Recent Updates
Recently added Catalysts
TAK Positive Sentiment

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Monday, August 24, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Takeda's ORZEYFUL (oveporexton) has been approved in Japan as the first and only medication to treat narcolepsy type 1. This innovative oral orexin receptor 2 agonist addresses the underlying cause of the condition, rather than just alleviating symptoms. The approval marks a significant advancement in narcolepsy treatment options.
Price reaction · baseline $18.18 (2026-08-21 close) · hit pre-market · clean, no other TAK news in the window
day 0 close
+0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • First-in-class treatment for narcolepsy type 1.
  • Holistic approach to treating the underlying cause.
  • Approval by the Japanese Ministry of Health.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+27%
120-day peak, hindsight
Typical move
1.4%
average across 15 past catalysts
Lead asset
SYR-472
Phase 1 · Healthy

Full Press Release Details

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine o

Frequently Asked Questions

What is ORZEYFUL used for?

ORZEYFUL is approved for treating narcolepsy type 1 in adults.

Who approved ORZEYFUL in Japan?

The Japanese Ministry of Health, Labour and Welfare approved ORZEYFUL.

What type of drug is ORZEYFUL?

ORZEYFUL is a first-in-class oral orexin receptor 2 agonist.

How does ORZEYFUL differ from other treatments?

It treats the underlying cause of narcolepsy type 1, not just symptoms.

ShareAdd on Google
Tags: TAK ORZEYFUL oveporexton narcolepsy type 1 Takeda Japan
Last updated: Aug 24, 2026

Biotech snapshot

Lead asset
SYR-472Phase 1
Healthy →

Catalyst track record

+27%
best trade around TAK's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for TAK.

See every catalyst's timing & PoA →